Company intelligence / Profile preview

Entia

London, United Kingdomentia.co ↗

Ownership: Private
Development stage: Other

Overview

Entia has developed Liberty, a home-use full blood count analyser that enables remote patient monitoring during cancer therapy. The device has been evaluated through four major trials involving thousands of patients across five NHS centres. It supports improved personalization and safety in cancer care by allowing clinicians to monitor patient blood counts remotely.

Therapeutic areas: Oncology
Industry: Physiological Monitoring

Partnerships

Collaborations with leading European cancer centrespartnerships with NHS providersinvestment backing from BGF and Parkwalk

Beyond the preview

Go deeper on Entia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entia.

Explore the full profile